Date: 2018-04-17
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Innate Pharma (France)
Product: antibody against Siglec-9
Action
mechanism: monoclonal antibody/immune checkpoint inhibitor.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 17, 2018, Innate Pharma announced that preclinical findings (ID: 2713) for a first-in-class antibody program targeting Siglec-9 have been presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, in Chicago. Siglecs comprise a family of 15 members of sialic acid bindingreceptors. Siglec-9 is an inhibitory receptor of the family that is expressed on a broad
range of immune cells of both lymphoid and myeloid origin. Siglec-9 can interact with sialic acids expressed by tumors, leading to dampened immune cell functions. Thus, Siglec-9-sialic acid interaction disruption may promote anti-tumor immunity. Data show that antibodies against Siglec-9 generated by Innate Pharma enhance NK cell cytotoxicity. This anti-tumor response is improved by the blockade of the immune checkpoint NKG2A. Further, data demonstrate that Siglec-9 is highly expressed on tumor-infiltrating myeloid cells and upregulated on T cells in cancer, suggesting a potential additional role as an inhibitory checkpoint agent.
Is
general: Yes
